Cost-effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China
Jian Ming, Yabing Zhang, Xun Xu, Mingwei Zhao, Yusheng Wang, Youxin Chen, Feng Zhang, Jiawei Wang, Jun Liu, Xinran Zhao, Rong Han, Shanlian Hu, Jian Ming, Yabing Zhang, Xun Xu, Mingwei Zhao, Yusheng Wang, Youxin Chen, Feng Zhang, Jiawei Wang, Jun Liu, Xinran Zhao, Rong Han, Shanlian Hu
Abstract
Aim: To evaluate the cost-effectiveness of intravitreal aflibercept compared with macular laser photocoagulation and ranibizumab for diabetic macular edema (DME) in China. Methods: A Markov model was developed to reflect the vision changes in DME patients. Parameters were estimated from VIVID-EAST trial data, published literature and physician surveys. Results: In a 20-year horizon, intravitreal aflibercept was associated with 7.825 quality-adjusted life years (QALYs) and 217,841 Chinese Yuan Renminbi (CNY), laser photocoagulation was associated with 7.189 QALYs and 135,489 CNY, and ranibizumab was associated with 7.462 QALYs and 222,477 CNY. The incremental cost-effectiveness ratios were 129,397 CNY/QALY and -12,774 CNY/QALY for intravitreal aflibercept versus laser photocoagulation and ranibizumab, respectively. Conclusion: Intravitreal aflibercept was considered as a cost-effective strategy for DME when compared with laser photocoagulation; it was considered as a dominant strategy when compared with ranibizumab.
Trial registration: ClinicalTrials.gov NCT01783886.
Keywords: cost–effectiveness analysis; diabetic macular edema; intravitreal aflibercept; macular laser photocoagulation; ranibizumab.
Source: PubMed